Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STING: Withdrawal vs maintenance of urate-lowering therapy guided by ultrasound in gout
2024-515714-40-00Phase 2Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of febuxostat and allopurinol in gout (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Proportion of patients with ≥1 gout flare at 24 months. Planned start Mar 2025; status: authorised.
02
Drugs
febuxostatallopurinol
03
Conditions
gout
Beyond the preview
Go deeper on 2024-515714-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515714-40-00.